Connecting Markets. Empowering People. Transforming Economies.
NiDCC

Insights

Insights and Intelligence

Home Insights and Intelligence

Intelligence for decisions, partnerships and market expansion.

Economic reporting from around the world, filtered to the sectors and policy areas our members build in — part of the same intelligence stream behind the Global Economic Outlook and NiDCC's market reports.

Thermo Fisher Scientific (TMO) Rolls Out New CHO K1 Media Panel For Biologics

life_sciences — September 24, 2026, 12:39 AM · Simply Wall Street

Thermo Fisher Scientific (TMO) Rolls Out New CHO K1 Media Panel For Biologics

Thermo Fisher Scientific (TMO) has launched the Gibco CHO-K1 Catalog Panel, a new cGMP-ready media and feed product designed for biologics development using CHO-K1 cell lines. This product aims to enhance protein production workflows, offering process optimization and scalability for drug developers. The launch strengthens Thermo Fisher's position in the bioproduction sector, supporting the bull case for the company, although existing concerns like high debt and external pressures remain.

Explore more
Regeneron Pharmaceuticals (REGN) Could Be 4% Undervalued Following Class Action Filing

life_sciences — September 23, 2026, 10:38 PM · Simply Wall Street

Regeneron Pharmaceuticals (REGN) Could Be 4% Undervalued Following Class Action Filing

Regeneron Pharmaceuticals (REGN) is currently seen as 4% undervalued despite a recent class action filing related to its Phase III Fianlimab Libtayo trial. While the company's stock has experienced a short-term dip, its broad pipeline in immunology, oncology, genetic medicines, and obesity continues to support future revenue and earnings growth. Investors are weighing the potential risks from the lawsuit and EYLEA pressure against the company's strong pipeline and fair value estimate of US$833.

Explore more
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

life_sciences — September 23, 2026, 10:17 PM · Yahoo Finance

DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

DexCom (DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer, a move seen as prioritizing continuity in leadership for global operations and quality. This aligns with DexCom's focus on execution for type 2 and prediabetes adoption, international expansion, and the ramp-up of its Ireland plant. Investors should monitor operational and margin commentary regarding the Ireland facility and global supply chain in future results to assess the impact of these changes.

Explore more
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care

life_sciences — September 23, 2026, 10:02 PM · Yahoo Finance

GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care

GSK is focusing on long-acting biologics and AI to innovate respiratory care, including twice-yearly treatments for asthma and COPD to improve patient adherence. The company is advancing pivotal programs for IL-33 and TSLP, exploring combination therapies, and expanding into pulmonary hypertension and MASH. Additionally, GSK is leveraging AI for clinical development, trial enrollment, and drug design, particularly in identifying optimal "target-trait pairings" and combination therapies.

Explore more
Corteva Starts Seed-Tech Trial Seeking $700 Million From Inari

life_sciences — September 23, 2026, 9:07 PM · Bloomberg Law News

Corteva Starts Seed-Tech Trial Seeking $700 Million From Inari

Corteva Inc. has initiated a trial in Delaware seeking $676.9 million from Inari Agriculture Inc., alleging the improper use of its protected soybean seed technology. The trial will determine if Inari, a startup, unlawfully used publicly available seeds or infringed on Corteva's patents to develop competing products. Jurors will hear conflicting accounts regarding the legality of Inari's actions.

Explore more
When Colorectal Cancer Strikes Early

life_sciences — September 23, 2026, 9:07 PM · Amgen

When Colorectal Cancer Strikes Early

Colorectal cancer rates are increasing worldwide, particularly among younger adults, becoming the leading cause of cancer death for those aged 25-49. The article highlights Anastasia's experience, a young aerospace engineer diagnosed with stage four colorectal cancer after dismissing early symptoms. Her story underscores the critical importance of recognizing symptoms, seeking medical attention promptly, and self-advocacy, as Amgen continues its commitment to research and awareness for this disease.

Explore more
FDA warns that certain Impella heart pump controllers may need serviced

life_sciences — September 23, 2026, 8:47 PM · Cardiovascular Business

FDA warns that certain Impella heart pump controllers may need serviced

The FDA has issued an early alert regarding new safety issues with specific Impella Automated Impella Controllers (AICs) from Johnson & Johnson MedTech. These devices require hardware, firmware, and/or software updates to address potential problems like the failure to recognize purge cassettes or unreliable buttons, though no serious injuries or deaths have been linked to these issues yet. Affected AICs can still be used for patient care while awaiting service, and this alert adds to a history of multiple recalls for the Impella platform.

Explore more
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

life_sciences — September 23, 2026, 8:24 PM · Investing News Network

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

MIMEDX announced a favorable federal court ruling regarding the regulatory classification of its product, AXIOFILL. The U.S. District Court for the Northern District of Georgia vacated FDA determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product, remanding the matters for further consideration. This ruling challenges the FDA's interpretation of minimal manipulation and its inconsistent classification of AXIOFILL compared to similar products.

Explore more
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

life_sciences — September 23, 2026, 8:24 PM · GlobeNewswire

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

MIMEDX Group, Inc. announced a favorable federal court ruling regarding the regulatory classification of its product, AXIOFILL. The court vacated the FDA's determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product, remanding the matters for further consideration. MIMEDX CEO Joseph H. Capper expressed satisfaction with the ruling, stating it addresses central issues and affirms the company's belief that AXIOFILL meets the requirements for classification as a Section 361 HCT/P.

Explore more
83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale

life_sciences — September 23, 2026, 8:20 PM · Stock Titan

83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale

A former officer of Ironwood Pharmaceuticals (IRWD), Michael Shetzline, has proposed selling 83,306 Class A common shares valued at approximately $377,376.18. This sale is intended to cover taxes associated with the vesting of stock awards. The transaction is scheduled for September 24, 2026, and is being handled through E Trade Securities LLC.

Explore more